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Abstract
Background: Genetic manipulation of poxvirus genomes through attenuation, or insertion of therapeutic genes has led to a
number of vector candidates for the treatment of a variety of human diseases. The development of recombinant poxviruses
often involves the genomic insertion of a selectable marker for purification and selection purposes. The use of marker genes
however inevitably results in a vector that contains unwanted genetic information of no therapeutic value.
Methodology/Principal Findings: Here we describe an improved strategy that allows for the creation of marker-free
recombinant poxviruses of any species. The Selectable and Excisable Marker (SEM) system incorporates a unique fusion
marker gene for the efficient selection of poxvirus recombinants and the Cre/loxP system to facilitate the subsequent
removal of the marker. We have defined and characterized this new methodological tool by insertion of a foreign gene into
vaccinia virus, with the subsequent removal of the selectable marker. We then analyzed the importance of loxP orientation
during Cre recombination, and show that the SEM system can be used to introduce site-specific deletions or inversions into
the viral genome. Finally, we demonstrate that the SEM strategy is amenable to other poxviruses, as demonstrated here
with the creation of an ectromelia virus recombinant lacking the EVM002 gene.
Conclusion/Significance: The system described here thus provides a faster, simpler and more efficient means to create
clinic-ready recombinant poxviruses for therapeutic gene therapy applications.
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Introduction
Poxviruses comprise a large family of double-stranded DNA
viruses that infect a wide range of hosts. Vaccinia virus (VV) is the
prototypic member of the Orthopoxvirus genus and the best-studied
virus in the poxvirus family. Since the eradication of smallpox [1],
VV and other poxvirus species have continued to be used for the
treatment of human disease [2,3] in part because a greater
understanding of poxvirus biology has led to safer and more
efficacious poxvirus-based therapeutics. The poxvirus genome is
easily genetically modified and can accommodate inserts exceed-
ing 25 kb [4] using strategies that are dependent upon virus-
encoded homologous recombination [5,6]. Using these approach-
es, recombinant VV has since proven to be valuable as a vector for
gene therapy in a number of therapeutic applications
[4,7,8,9,10,11,12,13,14,15]. Similarly, other members of the
poxvirus family have also been explored for their potential as
viral vectors for therapeutic purposes [9,10,16,17]. Genetically
engineered poxviruses that express immunogens from other
infectious agents have shown some promise as novel vaccines
against diseases like acquired immunodeficiency syndrome [11],
malaria [12], tuberculosis [18], and cancer [7,8,10,13]. As a
cancer vaccine, poxviruses have the potential to generate a strong
anti-tumoural immune response, especially when genetically
modified to express cytokines like IL-2 [14] or cell surface
receptors like CD70 that are indicative of oncogenic transforma-
tion [15]. Lastly, poxviruses have been successfully engineered as
oncolytic agents, offering the advantage of a strong anti-tumoural
immune response combined with cancer cell-specific replication
[7,16,17,19,20]. A number of these poxvirus candidates have
advanced to human clinical trials [10,11,12,13,19], highlighting
the therapeutic potential of poxvirus recombinants.
Poxvirus recombinants are typically produced by constructing a
plasmid containing the gene(s) of interest flanked by DNA
sequences homologous to the desired target locus, followed by
transfection of the plasmid into VV infected cells to allow for
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and the viral genome [21]. Using traditional approaches, the
frequency of recombination is typically less than 0.1% [22], and
the isolation of purified recombinant virus is tedious and time-
consuming. Recombinant poxviruses are often attenuated, and
have reduced growth kinetics and plaque size compared to their
wild type counterparts [23]. Historically, the target site of choice
has been VV thymidine kinase (Tk), but any non-essential locus
can be modified or disrupted in this manner. Recombinants are
then isolated and plaque purified. A number of selection methods
have been described including selection for Tk-positive or negative
phenotypes [21], and resistance to neomycin [24] or mycophenolic
acid (MPA) [25]. One can also use plaque assays to identify viruses
encoding b-galactosidase [26], b-glucuronidase [27], or fluores-
cent reporter constructs [28].
Although these methods work well and greatly facilitate the
recovery of recombinant viruses, the use of selectable markers
inevitably results in the creation of a product that contains genetic
information with no therapeutic value. Recombinant poxvirus
therapeutics would be considered safer vectors (most notably in the
view of regulatory agencies), if the selectable markers were
removed from the poxvirus genome [29]. Furthermore, the
expression of marker genes from recombinant poxviruses may
affect the overall fitness of the virus. Demmin et al. have shown that
the expression levels of neighboring genes can be affected by the
highly active transcription of marker genes incorporated into other
large DNA viruses [30].
To facilitate the removal of selectable markers, Falkner and
colleagues [31,32] developed transient selection methods wherein
a selectable marker is flanked by tandem DNA repeats. The virus
is stable while under selection, however the marker is lost through
VV dependent homologous recombination once the selection
pressure is removed. A similar system was employed by Alejo et al.,
to create ECTV recombinants [33]. Although these authors
describe efficiencies in excess of 90% for removal of the selectable
marker, the recombination reaction is a random and lengthy
process that relies on poxvirus machinery, and involves more than
six rounds of purification. Typically, the efficiency of poxvirus
recombination is quite low [22], recombinant viruses are often
attenuated and hard to propagate in the presence of wild-type
virus [34], and many time-consuming rounds of plaque purifica-
tion are needed to isolate the desired final viral product. An
improved technology is needed that allows for the specific,
controlled and efficient removal of selectable markers from
recombinant poxvirus genomes.
Here we define a new methodological tool for rapidly producing
marker-free recombinant poxviruses. This improved vector
development system, which we have termed Selectable and
Excisable Marker (SEM), takes advantage of the well-character-
ized Cre/loxP site-specific recombination system to efficiently
excise the reporter gene [35,36]. This strategy avoids the many
rounds of passage that are required when using virus recombina-
tion systems to excise genes flanked by tandemly duplicated
elements [31,32,33]. The SEM system offers the convenience of
positive selection of recombinants using both fluorescent and/or
drug-based strategies. Since recombinant poxvirus therapeutics
are often created with multiple gene knockouts (or knock-ins), the
SEM system was designed to be re-usable, therefore eliminating
the use of additional reporter genes that would otherwise
complicate and lengthen the overall cloning and selection
processes. To demonstrate the efficiency and utility of the method,
we have applied the SEM strategy to generate viruses with
targeted disruptions of different genes using two different poxvirus
species. Our results suggest that the SEM vector development
system will not only be useful for the creation of novel poxvirus
therapeutics, but also for basic virological studies.
Results
Characterization of the components of the SEM system
The Selectable and Excisable Marker system is summarized in
Fig. 1A. The first generation transfer vector pSEM-1 encoded a
foreign gene (firefly luciferase), a selectable marker as a fusion
between yellow fluorescent protein (yfp) and guanine phosphoribosyltransfer-
ase (gpt) genes, and loxP sites in the same orientation flanking the
selectable marker, with the target insertion site as the VV Tk locus
(Fig. 1B). To confirm that the expression of YFP was not
disrupted from the creation of the YFP-GPT fusion protein, YFP
expression was analyzed by western blot from U2OS cells either
mock-transfected (lane 1), or transiently transfected with either
pEYFP-C1 as a positive control (lane 2) or plasmids containing the
yfp-gpt fused gene (pEYFP-gpt or pEYFP-gpt-1loxP) in lanes 3 and
4, respectively (Figure S1A). The YFP and YFP-GPT fusion
proteins have predicted molecular weights of 26 and 45.5 kDa
respectively.
The cellular distribution of Cre from Cre recombinase-
expressing cell lines was analyzed by immunofluorescence from
parental U2OS cells (control), nuclear Cre cells (Nuc-Cre), and
cytoplasmic Cre (Cyto-Cre) cells illustrating that the absence of the
nuclear localization sequence in the Nuc-Cre cells leads to
accumulation of the enzyme in the cytoplasm (Fig. 1C). Cre
expression levels were compared among mock-transfected U2OS,
U2OS cells transiently transfected with pMC-Cre, and both stable
cell lines (Fig. 1D). In cells that were transiently or stably
expressing Cre-recombinase, anti-Cre western blot analysis
identified a band at 35 kDa, corresponding to the Cre enzyme.
The expression of Cre in the stable cell lines was 2-fold greater
when compared to the transiently transfected cells.
Isolation of a marker-free Tk-deleted, luciferase-
expressing VV using the SEM system
(YFP)-based fluorescence activated cell sorting (FACS) was
performed on mock infected U2OS cells as a control, and U2OS
cells that had been infected with a mixture of parental VV (Wyeth
strain), and recombinant VV generated from pSEM-1 expressing
the YFP-GPT fusion protein (VV-DTk-yfp-gpt)( Fig. 2A). To
ensure the highest possible FACS stringency, a cut-off of 0.5%
background fluorescence was maintained by comparing the mock-
infected U2OS cells to the recombinant YFP-expressing VV
infected U2OS cells (235 positive background cells from 47,421
U2OS cells counted, compared to 3004 positive recombinant VV
infected cells, from 49,498 U2OS counted). These sorted cells
were then mixed with uninfected U2OS cells, plated into multi-
well dishes, and subjected to two more rounds of YFP
+ plaque
purification.
To promote fast and simple removal of the yfp-gpt cassette from
recombinant viruses generated using the SEM system, viruses were
passaged on a U2OS cell line expressing a cytoplasmic form of Cre
recombinase. VV-DTk-yfp-gpt-1loxP (control virus) and VV-DTk-
yfp-gpt recombinant VV were passaged on either parental U2OS
cells, or U2OS cells stably expressing cytoplasmic Cre recombi-
nase (U2OS-Cre) (Fig. 2B). The U2OS cells were monitored for
both YFP fluorescence and for luciferase-mediated biolumines-
cence using the IVIS Imager (Xenogen) and Living ImageH v2.5
software. As shown in the top half of Fig. 2B, both VV-DTk-yfp-
gpt-1loxP control virus, and VV-DTk-yfp-gpt viruses express
luciferase and YFP when used to infect parental U2OS cells.
Infection of U2OS-Cre cells by the VV-DTk-yfp-gpt-1loxP and
Poxvirus Vector Development
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sion, however expression of YFP is only detectable from cells
infected with the VV-DTk-yfp-gpt-1loxP virus. This illustrates the
qualitative efficiency by which Cre-expressing U2OS cells excise
loxP-flanked markers, as well as the stability of the transgene
expression during the recombination reaction. To quantitatively
determine the efficiency of the Cre recombination reaction, U2OS
cells expressing Cre recombinase were infected with the VV-DTk-
yfp-gpt virus. Virus progeny was then analyzed for the percent YFP
positive versus negative virus plaques by U2OS plaque assay. As
seen in Figure 2C, both cytoplasmic and nuclear Cre expression
from stable cell lines resulted in nearly 100% efficiency for marker
gene excision, whereas transient transfection of Cre recombinase
was only 44% efficient.
The genomic composition of the VV recombinant viruses was
analyzed by PCR of viral DNA before and after removal of the yfp-
gpt cassette. A schematic of the virus genome at the Tk insertion
site is shown (Fig. 2D) to illustrate the primer pairs used in the
analysis. Primers were designed to amplify regions of DNA at the
insertion site (i and iv), surrounding the luciferase transgene (ii),
and across the yfp-gpt selectable marker (iii). For three of the PCR
reactions (primer pairs i, ii, and iv), the amplicons for each of the
viruses tested were the same and show that the Cre recombination
reaction does not affect the genome structure outside of the 2loxP
region (ii), and that the Tk locus was the site of homologous
recombination (i, iv) (Fig. 2E). Prior to passage on Cre-expressing
cells, PCR using primer pair (iii) of DNA from both VV-DTk-yfp-
gpt-1loxP and VV-DTk-yfp-gpt viruses produced bands at 1900 and
2000 bp, respectively. The 100 bp difference can be attributed to
the lack of one loxP site in the VV-DTk-yfp-gpt-1loxP virus. PCR of
DNA from the marker-free recombinant VV-DTk’ virus using
primer pair (iii), produced a much smaller band due to Cre-
mediated deletion of the yfp-gpt gene.
Genomic analysis and confirmation of identity of 3
independent clones of the VV-DTk-yfp-gpt and VV-DTk’
viruses
The genomic composition of the VV-DTk-yfp-gpt and VV-DTk’
viruses was analyzed by restriction enzyme digestion, southern blot
hybridization and sequencing analysis at the Cre-recombination
site (Fig. 3). Three independent clones of the VV-DTk-yfp-gpt virus
were compared to the parental VV Wyeth strain, before and after
passage on Cre-expressing cells. The DNA fragment containing
the Tk insertion site is highlighted (arrow) in the digest of the
parental VV Wyeth virus. Interestingly, the yfp-gpt cassette
included a HindIII restriction site. This led to a unique DNA
digest for the VV-DTk-yfp-gpt clones (Fig. 3A). The DNA
fragment containing the Tk insertion site is disrupted in digests
of the VV-DTk-yfp-gpt viruses, and is represented by unique bands
at ,6000 and ,2800 bp (see arrows, Fig. 3A). Digests of the VV-
DTk’ clones resemble the parental VV digest, since the yfp-gpt
cassette was removed by Cre-recombination. Importantly, the
southern hybridization for yfp demonstrates that there was only 1
insertion site of yfp-gpt during poxvirus homologous recombination
(Fig. 3B). DNA sequence analysis of the 3 VV-DTk’ clones was
performed to illustrate the consistency of the residual DNA
signature following Cre-recombination. A DNAStar sequence
alignment of the DNA from each of the 3 VV-DTk’ clones
Figure 1. Overview of the poxvirus Selectable and Excisable Marker cloning system. (A) Schematic illustrating the Selectable and
Excisable Marker poxvirus cloning system. (B) First generation poxvirus cloning vector pSEM-1 with labeled open reading frames. (C)
Immunofluorescence detection of Cre recombinase from U2OS cell lines expressing nuclear or cytoplasmic Cre, or control U2OS cells. (D) Western
blot analysis of Cre recombinase from U2OS cells mock transfected (U2OS), transiently transfected (pMC-Cre) or stably expressing Cre recombinase
targeted to either the nucleus or the cytoplasm (Nuc-Cre and Cyto-Cre respectively).
doi:10.1371/journal.pone.0024643.g001
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predicted, the residual DNA signature contained 1 loxP site and
remnants from the pSEM-1 vector.
Construction of the second generation SEM cloning
vector and the VV-DI4L viruses
The second generation SEM plasmid, termed pDGloxPKO was
designed with multiple cloning sites flanking the yfp-gpt cassette.
This permits insertion of homologous targeting sequences flanking
the selectable marker and/or therapeutic transgene. This vector
was also designed such that the yfp-gpt cassette and its early/late
viral promoter are flanked by loxP sites. To test the importance of
loxP site orientation during Cre-recombination, two pDGloxPKO
vectors were created with the loxP sites in either the same
orientation (pDGloxPKO
DEL)( Figure S2A), or oriented towards
each other (pDGloxPKO
INV)( Figure S2B). Inserting homolo-
gous sequences of DNA from the VV genome flanking the I4L
gene (I3L and I5L homology) into both pDGloxPKO
DEL and
pDGloxPKO
INV vectors generated pDGloxPKO
DEL-DI4L and
pDGloxPKO
INV-DI4L, respectively (Fig. 4A and 4B). These
vectors were used to create two strains of recombinant VV in
which the I4L locus is disrupted by vector-derived yfp-gpt cassette
sequences(seeschematicinFig. 4C). Using vector pDGloxPKO
DEL-
DI4L, which contains identically oriented loxP sites flanking the
Figure 2. FACS purification of recombinant VV-DTk infected cells and Cre-recombinase mediated removal of the selectable marker.
(A) Dot plot of YFP fluorescence versus side scatter from Fluorescence Activated Cell Sorting (FACS) analysis of U2OS cells mock infected, or infected
with a mixture of parental VV and recombinant VV virus expressing YFP. (B) Purified recombinant VV-DTk-yfp-gpt-1loxP (control virus) or VV-DTk-yfp-
gpt virus were used to infect stable cytoplasmic Cre-expressing cells (U2OS-Cre) or parental U2OS cells in 6-well plates, and were monitored for
foreign gene expression (firefly luciferase) and marker gene expression (YFP-GPT fusion protein). (C) Percent YFP-negative VV-DTk’ plaques on U2OS
cells after passage of virus on Cre cells (nuclear or cytoplasmic stable cell lines or transiently transfected U2OS cells). (D) Map of the pSEM-1 plasmid
indicating the primer pairs used in the PCR reactions to characterize the genome of recombinant VV-DTk viruses shown in panel E.( E) PCR analysis of
DNA extracted from VV-DTk-yfp-gpt-1loxP (control virus), VV-DTk-yfp-gpt and VV-DTk’ viruses. The PCR products span: i. across the left Tk flanking
region, ii. across the luciferase gene, iii. across the yfp-gpt selectable marker, iv. across the right the Tk flanking region. n.s=not-significant,
* p=0.001.
doi:10.1371/journal.pone.0024643.g002
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DEL,
whereas using vector pDGloxPKO
INV-DI4L in which the inserted
yfp-gpt cassette is flanked by loxP sites oriented towards each other
generated virus VV-DI4L
INV. The genomic composition of the
VV-DI4L
DEL virus post Cre passage was analyzed by sequencing
at the excision site of yfp-gpt and revealed the Cre/loxP signature
remaining in the viral genome post Cre-recombination (Fig. 4D).
As expected, the virus contains 1 loxP site, and remnants from
the pDGloxPKO vector. To exclude the possibility that there
were multiple yfp-gpt insertion sites, the entire genome of VV-
DI4L
DEL virus post Cre passage was sequenced. The sequence of
the VV-DI4L
DEL recombinant was compared to the sequence of
the parental VV (Western Reserve) using a dotplot analysis
(Figure S3A). These data illustrate that the VV-DI4L
DEL virus is
disrupted only at the I4L locus, thereby confirming 1 insertion
site at the desired locus.
Cre-mediated recombination of viral DNA is dependent
upon loxP site orientation
Both the pDGloxPKO
DEL and pDGloxPKO
INV plasmids were
used to explore the dependence of loxP orientation on Cre-mediated
recombination of poxvirus genomes. Previous work has shown that
Cre-mediated recombination between identically-oriented loxP sites
generates deletions while oppositely oriented loxP sites lead to
inversion of DNA sequences [35,36], but it remained to be formally
proven that this would also hold-true in virus-infected cells.
Recombinant DI4L viruses were analyzed by PCR for the presence
of the I4L gene before (BSC-40 passage) and after (U2OS-Cre
passage) Cre recombination (Fig. 5A). As an additional test of the
SEM approach, we have included F4L-inactivated recombinants in
these experiments, as DF4L virus backgrounds have been reported to
have severe growth kinetics compared to their wild-type counterpart
[23]. Referring to the expected amplicon sizes and primer pairs
illustrated in Fig. 4C, the PCR products generated using primers
flanking the yfp-gpt cassette (A+D) exhibited sizes indicative of
replacement of the I4L gene with the yfp-gpt cassette in viruses
cultured in BSC-40 cells (Fig. 5A, left panel). Upon passage in Cre-
expressing cells, only those viruses produced using pDGloxPKO
DEL
vectors (DI4L
DEL,a n dDI4L/DF4L
DEL) exhibited the deletion of the
yfp-gpt cassette (Fig. 5A, right panel). This shows that Cre-mediated
deletions only occur when the DNA is flanked by identically oriented
loxP sites.
The orientation of the yfp-gpt cassette in recombinant viruses
produced using the pDGloxPKO
INV-DI4L vector were also
analyzed by PCR before and after passage through Cre-expressing
cells. We used primer pairs designed to amplify the yfp-gpt cassette
Figure 3. Confirmation of genomic composition of 3 independent recombinant VV-DTk viruses. (A) An ethidium bromide stained DNA
gel of genomic HindIII restriction digests of viral DNA isolated from parental VV (Wyeth Strain), 3 clones of VV-DTk-yfp-gpt and 3 clones of VV-DTk’.
Arrows indicate the Tk insertion site (VV-Wyeth), and the unique bands that result from insertion of the yfp-gpt cassette (VV-DTk-yfp-gpt). (B) Southern
hybridization of the DNA gel in A identifying the yfp insert present in the genome of the VV-DTk-yfp-gpt clones, but not in parental VV-Wyeth or the
VV-DTk’ clones. (C) DNAStar sequence alignment at the yfp-gpt insertion site of DNA isolated from the 3 VV-DTk’ clones post Cre passage.
doi:10.1371/journal.pone.0024643.g003
Poxvirus Vector Development
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of yfp-gpt inversions (pairs A+C, B+D). The viruses isolated from
BSC-40 cells produced PCR products consistent with a single
orientation identical to that seen in original plasmid (Fig. 5B, left
panel). However, upon passage through Cre-expressing cells, the
PCR products displayed a pattern characteristic of a mix of two
different arrangements of loxP flanked inserts (Fig. 5B, right
panel).
Western blot analysis was used to confirm deletion of the I4L
locus of all DI4L strains. Recombinant DI4L viruses produced with
either pDGloxPKO
INV-DI4L or pDGloxPKO
DEL-DI4L vectors
led to inactivation of I4 protein expression and this inactivation
was specific since I3, (expressed from the neighbouring gene, I3L)
levels remained unchanged (Fig. 5C). The YFP-GPT protein was
only deleted from strains that had been generated with the
pDGloxPKO
DEL-DI4L targeting vector and passaged in Cre-
expressing cells (Fig. 5C, right panel), further confirming that
deletion events need both identically-oriented loxP sites and
exposure to Cre activity. Collectively, these results demonstrate
that the SEM vector system can be used to either delete or invert
sequences within the viral genome, upon passage of the selected
strains in Cre-expressing cells.
The SEM system can be used with other members of the
Poxvirus family
The SEM system was also used to create a recombinant ECTV
(strain Moscow) lacking the EVM002 gene using the transfer
plasmid pDGloxPKO
DEL-DEVM002 (Fig. 6A). Referring to the
schematic outlined in Fig. 6B, ECTV viral recombination with
pDGloxPKO
DEL-DEVM002 with subsequent MPA drug selection
created the primary recombinant ECTV-DEVM002-yfp-gpt. The
virus was passaged through U2OS-Cre cells to obtain the marker-
free recombinant virus ECTV-DEVM002’. The genomic compo-
sition of wild type ECTV (ECTV-wt), ECTV-DEVM002-yfp-gpt,
and ECTV-DEVM002’ viruses was confirmed by PCR analysis
(Fig. 6C). These PCR analyses demonstrate at the genomic level
the deletion of the EVM002 gene, the insertion of the yfp-gpt
cassette, and its subsequent removal following Cre-mediated
recombination. The genomic composition of the ECTV-
DEVM002’ was analyzed by sequencing at the excision site of
yfp-gpt to illustrate the Cre/loxP signature remaining in the viral
genome post recombination (Fig. 6D). As expected, the virus
contains 1 loxP site, and remnants from the pDGloxPKO vector.
YFP protein expression from the ECTV viruses was also analyzed
by confocal microscopy (Fig. 6E). Mock-infected BGMK cells
Figure 4. Creation of the VV-DI4L mutants from the second generation SEM cloning vectors. (A) Map of cloning vector pDGloxPKO
DEL-
DI4L and (B) pDGloxPKO
INV-DI4L with labeled open reading frames. (C) Schematic displaying the strategy for knock-out of the I4L open reading frame
from VV strain WR, and possible outcomes of Cre-recombination of recombinant VV-DI4L virus generated from either the pDGloxPKO
DEL-DI4L or
pDGloxPKO
INV-DI4L vectors. (D) DNA sequence analysis of the VV-DI4L
DEL virus post Cre passage.
doi:10.1371/journal.pone.0024643.g004
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ECTV-DEVM002’ infected cells for YFP fluorescence. Only those
cells that were infected with recombinant ECTV-DEVM002-yfp-gpt
expressed detectable levels of YFP fluorescence.
Discussion
Poxviruses have been, and will continue to be, important
therapeutics for the prevention and treatment of human diseases
[2,3,10,11,12,13,19]. Arguably, the application of VV for the
eradication of smallpox has been one of the most important
medical advances in human history. A variety of poxvirus based
vaccine vectors have been developed for both human and
veterinary infectious diseases and more recently as agents for the
treatment of cancer [2,7,8,10,13,14,15,16,17,19,20]. During
therapeutic development it is desirable to use marker genes for
both construction of novel vectors but also for pre-clinical and
even early phase clinical experimentation. Unfortunately as
products mature, there becomes a transition point where marker
genes are no longer necessary and, in the view of regulatory
agencies, may even compromise the safety of the vector [29].
The SEM system provides a faster, simplified and more efficient
means to create marker-free recombinant poxviruses [31,32,35]. As
outlined in Fig. 1A, the SEM cloning strategy can be summarized in
three basic steps: transfection of poxvirus-infected cells with an SEM
vector, purification of resulting recombinants through FACS and/or
drug selection, and finally removal of the selectable marker by virus
passage in Cre-expressing cells. The first generation pSEM-1 vector
(Fig. 1B) was created to demonstrate the ‘‘proof of principle’’ that it
was possible to create marker-free recombinant poxviruses with our
system, while stably retaining a functional transgene (in our case
luciferase) during the Cre-recombination reaction (Fig. 2B). The
second generation SEM plasmids (Figure S2) broaden the
applicability of the SEM system to other poxvirus loci, and other
poxvirus genera by the insertion of two multiple cloning sites (MCS)
flanking the yfp-gpt cassette and loxP sites. Sequences homologous to
Figure 5. Cre-mediated recombination of vaccinia virus DNA is dependent upon loxP site orientation. (A) PCR analysis of the I4L locus
using primers flanking the yfp-gpt cassette of two purified DI4L strains generated from either the pDGloxPKO
DEL-DI4L or pDGloxPKO
INV-DI4L vectors
before (BSC-40) and after (U2OS-Cre) Cre-recombination. (B) PCR analysis of two purified DI4L strains generated from the pDGloxPKO
INV-DI4L vector
with primers amplifying inside and outside the yfp-gpt cassette before (BSC-40) and after (U20S-Cre) Cre-recombination. (C) Western blot analysis of
two purified DI4L strains generated from either the pDGloxPKO
DEL-DI4L or pDGloxPKO
INV-DI4L vectors for I4, YFP, I3 (positive control for infection) and
actin before (BSC-40) and after (U20S-Cre) Cre-recombination.
doi:10.1371/journal.pone.0024643.g005
Poxvirus Vector Development
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have demonstrated with the ectromelia virus recombinant construct-
ed from pDGloxPKO
DEL-DEVM002 (Fig. 6).
The most labour-intensive part of traditional poxvirus cloning
strategies is the isolation and purification of desired recombinants
from a heterogeneous population. To simplify the isolation of pure
recombinant poxvirus clones, we have included both drug (gpt) and
optical (yfp) selection strategies in the SEM system. The flexibility
and simplicity of this approach ensures that the SEM system will
be amenable to any research laboratory. MPA drug selection is
relatively inexpensive and historically has shown to be an efficient
means to purify poxvirus recombinants [25]. Indeed, we have
shown here that MPA selection alone is sufficient to isolate a pure
recombinant poxvirus population in as few as three passages (e.g.
VV-DI4L, Fig. 4 and ECTV-DEVM002, Fig. 6). We have also
shown the usefulness of fluorescent sorting strategies to rapidly
enrich for the recombinant virus population by subjecting the
initial transfection/infection reaction to FACS analysis (Fig. 2A).
Alternatively, a more traditional approach of using fluorescent
microscopy to identify and pick individual plaques expressing YFP
can be used. The flexibility of the SEM system in the purification
of recombinant poxviruses is particularly important when working
with highly attenuated strains. Importantly, we show here that
even the double deleted DI4L/DF4L VV strains, which have
severe replication defects and exhibit a small plaque phenotype
[23], can be produced and purified using the SEM system.
We had hypothesized that expression of cytoplasmic Cre-
recombinase would maximize recombination efficiency since
poxviruses replicate in the cytoplasm. Indeed a single passage of
the VV-DTk-yfp-gpt virus on U2OS cells expressing cytoplasmic
Cre is sufficient to eliminate nearly all of the yfp-gpt cassette from
the viral genome (Fig. 2B and 2C). However, infection of U2OS
cells stably expressing nuclear Cre still led to nearly 100%
recombination efficiency (Fig. 2C). Not unlike other proteins,
the Cre enzyme is initially located in the cytoplasm prior to
transport to the nucleus. We speculate that in cells selected for
high levels of Cre expression, the amount of enzyme is not limiting
for the excision reaction and thus even small amounts, or
temporary cytoplasmic expression of Cre from nuclear-cre
expressing cells may be sufficient to facilitate recombination.
Importantly, despite lower Cre-expression levels achieved from
transient transfection of U2OS cells with pMC-Cre (Fig. 1D), the
recombination frequency was still .40% (Fig. 2C). These data
illustrate how the SEM system can be used with any transfectable
cell line while maintaining the efficiency of the Cre/loxP reaction.
To confirm that the residual DNA signature was consistent for
all recombinant viruses post Cre recombination, DNA sequencing
was performed at the insertion site (Figs. 3C, 4D, 6D). In all
cases, one 34 base pair loxP site remains in the viral genome, with
some remnants of the respective SEM cloning vectors. We have
observed no obvious impact of retention of this 34 base pair
sequence on virus replication and indeed this has been studied
Figure 6. Generation of a recombinant ECTV using SEM. (A) Map of pDGloxPKO
DEL-DEVM002 with labeled open reading frames. (B) Schematic
displaying the strategy for knock-out of the EVM002 open reading frame from ECTV. (C) PCR analysis of viral DNA. Primers were used to amplify the
regions of pDGloxPKO-DEVM002 homology from wild-type ECTV (ECTV-wt), ECTV-DEVM002-yfp-gpt, and ECTV-DEVM002’.( D) DNA sequence analysis
of the ECTV-DEVM002’ virus (post Cre passage). (E) Confocal microscopy was used to detect YFP fluorescence in mock infected BGMK cells or BGMK
cells infected with ECTV-wt, ECTV-DEVM002-yfp-gpt, or ECTV-DEVM002’. A 406magnification lens was used to detect differential interference contrast
(DIC), and YFP fluorescence.
doi:10.1371/journal.pone.0024643.g006
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sequences has no impact on mRNA stability, promoter activity or
genome integrity [37,38]. To further validate the consistency of
the recombination events of the SEM system, 3 clones of the VV-
DTk virus pre (VV-DTk-yfp-gpt) and post (VV-DTk’) Cre passage
were analyzed by HindIII DNA restriction digest and southern
hybridization (Fig. 3). As predicted, the DNA signatures are
consistent, and the Tk locus is the only site of poxvirus
recombination. Since the VV-DI4L and ECTV-DEVM002’
recombinant viruses were purified as heterogeneous populations
(MPA drug selection), the sequence analysis is representative of all
recombination events. To confirm that there was only 1 site of yfp-
gpt integration in the VV-DI4L
DEL virus, the entire genome of the
virus was sequenced. A dotplot comparison of recombinant VV-
DI4L
DEL to parental VV illustrates that the recombination event
was targeted to the I4L locus (Figure S3).
Using the second generation SEM cloning vectors (pDGloxP-
KO
DEL and pDGloxPKO
INV), we have shown for the first time
that similar to recombination of cellular DNA [35,36], Cre-
mediated recombination between identically-oriented loxP sites
generates deletions, while oppositely oriented loxP sites leads to
inversions of viral DNA sequences (Fig. 5). Interestingly, targeted
inversions of the yfp-gpt cassette when generating viruses using the
pDGloxPKO
INV-DI4L targeting vector identified an additional
application for the SEM system. Site-specific inversions may be
useful for transcriptional interference studies [39] in which a
poxvirus promoter could drive the same mRNA from opposite
strands. This approach would allow one to assess the potential
strand-specific influence of neighbouring transcriptional processes
and read-through transcripts on the efficiency of transcription of
the reporter mRNA.
In summary, the SEM strategy provides an efficient means to
‘‘surgically’’ manipulate viral genomes by adding or deleting genes
without leaving unwanted marker genes behind. We have
demonstrated the applicability of the SEM system to create
recombinant viruses in two different species, targeting three
different poxvirus loci by deletions and/or insertions, including
strains with severe replication defects. By inclusion of fluorescence
and drug selection strategies, the SEM system offers both flexibility
and simplicity for the purification of recombinant viruses. The yfp-
gpt cassette was also shown to be useful during Cre-recombination
to monitor efficiency, which could be enhanced even further by
making use of a reverse gpt selection strategy [40]. This system will
be especially useful when multiple deletions or transgenes are to be
added sequentially to a single vector. Finally, the tools developed
in the SEM system may also contribute to basic virology research,
like those that involve transcriptional interference studies.
Materials and Methods
Antibodies and reagents
The following primary antibodies were used: rabbit anti-GFP/
YFP (Abcam), Cre (Novagen), VV I4 (a gift from Dr. C. Mathews,
Oregon State University), mouse anti-b-actin (Sigma-Aldrich) and
VV I3 [41]. Secondary antibodies conjugated to horseradish
peroxidase (BioRad) or infrared dyes (Li-Cor) were used to detect
primary antibodies in immunoblotting. OptiMEM (Invitrogen)
was used for transfection experiments.
Cells
The following cells were purchased from American Type Tissue
Collection: human osteosarcoma (U2OS), human embryonic
kidney, large T antigen transformed (293T), and green monkey
kidney (BSC-40) cells. Buffalo green monkey kidney (BGMK) cells
werepurchased fromDiagnosticHybrid.Celllineswere maintained
in Dulbecco’s modified Eagle’s medium (Hyclone) supplemented
with 10% fetal calf serum (Cansera), penicillin (100 U/ml), and
streptomycin sulfate (100 mg/ml) at 37uCi n5 %C O 2. All cell lines
were tested and found clear of mycoplasma contamination.
Plasmids
Plasmids pEYFP-C1, pLPCX, and pLXSN were purchased
from Clontech and pGEM-T was purchased from Promega.
Plasmid pMC-Cre [42] was a gift from Dr. Klaus Rajewsky
(Harvard Medical School), pSEL-eGFP [20] and pSC65-luc [43]
were gifts from Dr. David Bartlett (University of Pittsburgh) and
pHIT60 and pHIT456 were gifts from Dr. Ian Lorimer
(University of Ottawa).
Cloning – pSEM-1 vector
The gpt gene was first excised from pSEL-eGFP with BseY1,
repaired, and ligated into a pT7blue-3 cloning vector (Novagen).
The gpt gene was then excised with SalI and BamHI and ligated, in
frame, into XhoI/BamHI cut pEYFP-C1. This created pEYFP-gpt
bearing a fusion of the two polypeptides. The first loxP sequence
was constructed by annealing together two oligonucleotides with
the same sequence (loxP, Table S1), using the In-Fusion-2
method (Clontech) [44]. The pEYFP-gpt plasmid was then cut
with NheI and recombined with the double-stranded DNA loxP
site to obtain ploxP-EYFP-gpt. The second loxP sequence was
inserted in a similar way by cutting ploxP-EYFP-gpt at the BamHI
site, and inserting the double-stranded oligonucleotide loxP
(Table S1). The resulting plasmid, p2loxP-EYFP-gpt, contained
two loxP sites with the same orientation flanking the gene
encoding the YFP-GPT fusion protein.
ThepSEM-1plasmid wasassembledbyinsertingthe loxP-yfp-gpt-
loxP cassette into pSC65-luc. This was accomplished by cutting
p2loxP-EYFP-gpt and pSC65-luc plasmids with XhoI and BamHI
restriction enzymes, and ligating the loxP-yfp-gpt-loxP insert into the
VV Tk gene in pSC65-luc. Two vectors were created: a negative
control vector containing only the first loxP site (pSEM-1ctrl), and a
vectorcontaining two loxPsites inserted in the sameorientation and
flanking the reporter construct (pSEM-1) (Fig. 1B).
Cloning – pDGloxPKO vectors
A second series of vectors were assembled using gene synthesis
(GeneArt) and contained two multiple cloning sites flanking the
loxP sites. To test the importance of loxP orientation, two versions
of these plasmids were created with the loxP sites either in the
same (pDGloxPKO
DEL) or in the opposite orientation (pDGloxP-
KO
INV) with respect to one another (Figure S2).
Cloning – pDGloxPKO-DI4L vectors
The PCR and primers I5L (left) plus I5L (right) (Table S1)
were used to prepare a ,430 bp PCR product encoding
sequences flanking the ‘‘I5L’’ side of the VV I4L locus. Similarly
the PCR and primers I3L (left) plus I3L (right) (Table S1) were
used to produce a ,340 bp PCR product containing sequences
flanking the ‘‘I3L’’ side of the I4L locus. These DNAs were then
cloned into the SpeI/SalI( I5L homology) and SacII/BglII (I3L
homology) restriction sites of pDGloxPKO
INV and pDGloxPKO-
DEL. Adding these sequences created vectors pDGloxPKO
INV-
DI4L and pDGloxPKO
DEL-DI4L (Fig. 4).
Cloning – pDGloxPKODEL-DEVM002 vector
The PCR and primers EVM002-59 (left) plus EVM002-59
(right) (Table S1) were used to prepare a 150 bp product
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PCR and primers EVM002-39 (left) plus EVM002-39 (right)
(Table S1) were used to produce a 150 bp product encoding
sequences to the right of the EVM002 gene in the ectromelia virus
(ECTV) genome. These two 150 bp PCR fragments were cloned
into pGEM-T vectors (Promega). The fragment encoding
sequences located on the left side of the EVM002 gene was
subsequently cloned into the pDGloxPKO
DEL vector using the
XhoI and HindIII restriction sites to create pDGloxPKO-EVM002-
59. Finally, the EVM002-39 150 bp was cloned into pDGloxPKO-
EVM002-59 using the BamHI and NotI restriction sites to create
pDGloxPKO
DEL-DEVM002.
Cloning – Cre plasmids
The gene encoding a form of Cre protein lacking a nuclear
localization sequence (NLS) was PCR amplified from pMC-Cre
using Taq polymerase and primers NLS-free Cre (left) and NLS-
free Cre (right) (Table S1). The PCR product was digested with
XhoI and NotI and ligated into pLPCX cut with the same enzymes.
This produced plasmid pLPCX-Cyto_Cre. A Cre plasmid was
also created with the NLS intact by digesting Cre from pMC-Cre,
and inserting the gene into the XhoI site of the pLXSN vector to
form pLXSN-Nuc_Cre.
U2OS-Cre cells
Retroviral transduction methods were used to produce cells
expressing nuclear- or cytoplasmic-localized Cre protein. A stock
of transducing particles was first produced by using calcium
phosphate to co-transfect 293T cells with 7 mg of plasmid DNA
(either pLPCX-Cyto_Cre or pLSXN-Nuc_Cre) along with the
retroviral helper plasmids pHIT60 and pHIT456 [45]. Virus-
containing supernatants were harvested two days later and the
debris removed with a 0.45-mm filter. To perform the transduction
experiment, 2.5610
5 U2OS cells were infected with 2 mL of the
virus for 2 hr in the presence of 8 mg/mL of polybrene. Two days
later, G418 (800 mg/mL) or puromycin (1 mg/mL) were added
and drug-resistant recombinants were harvested a week later.
Purified recombinant poxviruses were passaged 1-to-3 times in
these cells to remove loxP-flanked genes.
Recombinant viruses
Viruses constructed from the pSEM-1 vector were produced
from the VV strain Wyeth [7]. U2OS cells were infected with VV
at a multiplicity of infection (MOI) of 0.01 and then transfected
with plasmid pSEM-1 or pSEM-1ctrl vectors using Lipofectamine
2000 (Invitrogen). The cells were incubated at 37uC for 4 hr, the
medium was replaced, and then the cells cultured for two more
days. The dishes were harvested, YFP-positive cells sorted using
flow cytometry, and the YFP-positive population purified further
by selecting YFP-positive plaques in the presence of MPA for 2
rounds of purification. This produced VV strain VV-DTk- yfp-gpt
with both loxP sites in the same orientation and VV strain VV-
DTk-yfp-gpt-1loxP bearing a single loxP site.
Viruses bearing deletions of the I4L gene were produced using
pDGloxPKO
INV-DI4L and pDGloxPKO
DEL-DI4L vectors in VV
strain Western Reserve (WR), and in DF4L VV strains [23]. BSC-
40 cells were infected for 1 hr (MOI=2), transfected with plasmid
DNA using Lipofectamine 2000, and virus harvested two days
later. Recombinant virus were isolated using three rounds of
plaque purification on BSC-40 cells in MPA selection media
(DMEM supplemented with 10% serum, 50 U/mL penicillin,
50 mg/mL of streptomycin, 200 mM glutamine, 250 mg/mL
xanthine, 15 mg/mL hypoxanthine, and 25 mg/mL MPA).
A recombinant ECTV was constructed by infecting BGMK
cells with ECTV (strain Moscow) at an MOI=0.01, followed by
transfection with XhoI and NotI linearized pDGloxPKO-
DEVM002 DNA. The virus was harvested two days later and
foci were purified twice in the presence of MPA and twice in the
absence of MPA selection.
Cell sorting and flow cytometry
U2OS cells were infected with virus at MOI ,0.1 for 6 hr, and
sorted for YFP fluorescence on a MoFlo cytometer (DakoCytoma-
tion). The top 5% of YFP positive cells (approximately 3,000 cells)
were collected and mixed with ,300,000 uninfected U2OS cells
and cultured for two days in a 10 cm dish. For flow cytometry,
,10
6 HeLa cells were infected with virus at a MOI=3 for 4 hr.
The cells were suspended in 0.5 mL of PBS containing 1% FBS,
and YFP fluorescence determined using a FACScan flow
cytometer (Becton-Dickinson) and CellQuest software (Version
3.1).
Luciferase and fluorescence detection using IVIS Imager
The fluorescence and bioluminescence were detected using a
200 Series IVIS Imager (Xenogen) and Living ImageH v2.5
software. Cell lysates from Cre cell lines infected with VV-DTk-
yfp-gpt were used to infect U2OS cells which were first imaged for
YFP fluorescence prior to incubation with 20 mg of D-luciferin
(Molecular Imaging Products Company) added directly to the
cultured cells. D-luciferin was incubated with the cells for 20 min
at 37uC. Identical program settings (exposure, aperture and pixel
binning) were used for all experiments.
Quantification of Cre recombination efficiency
U2OS cells stably expressing nuclear or cytoplasmic versions of
U2OS, or U2OS cells transiently transfected with Cre recombi-
nase were infected at an MOI of 0.05 for 2 days. Virus progeny
was then analyzed by U2OS plaque assay for YFP expression of
individual virus plaques.
Fluorescence microscopy
To detect YFP, 2610
5 BGMK cells were seeded on coverslips
and infected (or mock infected) with virus at a MOI=0.01 for two
days. The cells were fixed with 2% paraformaldehyde, mounted in
50% glycerol containing 4 mg/mL N-propyl-gallate (Sigma-
Aldrich), and 250 mg/mL 4,6-diamidino-2-phenylindole (DAPI)
(Invitrogen), and visualized using a Zeiss 710 confocal microscope
equipped with Zeiss Zen software 2009, light edition. For
immunofluorescence microscopy, 5610
4 Cre-expressing U2OS
cells were plated per 1.8 cm
2 well in Nunc Chamber SlidesH. The
cells were washed three times with PBS and fixed with 4%
paraformaldehyde for 10 min at room temperature. The cells were
treated for 30 min with blocking buffer (0.2% Triton X-100, 5%
normal goat serum in PBS) and then incubated overnight at 4uC
with a 1:100 diluted anti-Cre antibody in blocking buffer. The cells
were washed with PBS, incubated for 30 min with Cy3–
conjugated goat anti-rabbit antibody (Jackson), washed three
times, and then mounted on a slide. DNA was stained with
1.5 mg/mL 4,6-diamidino-2-phenylindole (DAPI). Cell images
were captured using a Zeiss Axioplan 2 microscope equipped
with Axioview 3.1 software.
Virus DNA extraction
DNA was extracted from sucrose cushion purified virus stocks
according to methods adapted from Meyer et al. [46]. Briefly,
200 mL of purified virus stock was treated with lysis buffer (1.4 mL
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proteinase-K and 250 mL 10% SDS) for 4 hours at 55uC. The
samples were then purified by phenol extraction.
Sequencing of viral DNA
Viral DNA from Cre-passaged viruses was subjected to PCR
amplification at the site of Cre recombination. Sequencing was
performed using the Applied Biosystem DNA analyzers. The
entire genome of both parental VV Western Reserve and
recombinant VV-DI4L
DEL virus post Cre passage were sequenced
from 5 mg of extracted viral DNA at the Genome Que ´bec
Innovation Centre (Montre ´al, Que ´bec) using a high throughput
pyrosequencing approach on a Roche 454 GS FLX Titanium
sequencer platform. CLC Genomics Workbench 4.6 software was
used to assemble the genome sequence. The viral genomes were
analyzed and compared using dotplots prepared using the
program Gepard [47] with default settings.
DNA restriction digest and southern hybridization
Viral DNA was analyzed using Southern blot. Briefly, 7 mgo f
DNA was digested overnight with HindIII restriction enzyme
(Invitrogen) at 37uC. DNA digests were electrophoresed on a 0.8%
agarose gel in 16 TAE buffer at 46 V for 6 hours, then stained
with ethidium bromide and photographed. Gels were first
denatured for 45 mins, then neutralized for 45 mins prior to
transfer over night onto Hybond-N membrane (Amersham), and
finally UV cross-linked. A 931 bp yfp-gpt probe was labeled with
P
32 a-dCTP (PerkinElmer) using the Multiprime DNA Labeling
kit (Amersham). The blot was blocked for 2 hours at 42uCi na
formamide pre-hybridization buffer followed by over night
hybridization with 5 mCurries of denatured probe. Membranes
were washed and exposed to a phospho screen for 18 hours and
imaged on a Storm imaging system (Storm 860; Molecular
Dynamics) using ImageQuant software, version 5.2.
Western blotting
For immunoblotting, cells were lysed in RIPA buffer with
protease inhibitors (CompleteH, Roche) for 30 min on ice. The cell
lysates were sonicated for 30 seconds, centrifuged at 10,0006g and
the cell pellets discarded, fractionated by electrophoresis on a
Nupage 4–12% Bis-Tris gel (Invitrogen), transferred to Hybond-C
extra nitrocellulose membranes (Amersham), and probed with the
indicated primary antibodies. Secondary antibodies conjugated to
horseradish peroxidase or Li-Cor infrared dyes were used to detect
bound antigens.
Statistical Analysis
Data were analyzed by a one-way Anova, followed by a Turkey
post-hoc for multiple group comparison at a 99% confidence
interval.
Supporting Information
Figure S1 Detection of YFP protein expression by
western blot analysis. (A) Western blotting of transfected cells.
Anti-YFP western blot of U2OS cells mock transfected (1), or
transfected with plasmid DNA pEYFP-c1 (2), pEYFP-gpt, (3), or
pEYFP-gpt-1loxP (4).
(TIFF)
FigureS2 PlasmidmapsofpDGloxPKO
DEL andpDGloxP-
KO
INV. (A) Map of cloning vector pDGloxPKO
DEL and (B)
pDGloxPKO
INV with labeled open reading frames.
(TIFF)
Figure S3 Sequencing analysis of genomic viral DNA
from VV-DI4L
DEL. (A) Dotplot comparison of sequenced viral
genomes of wild type Western Reserve vaccinia virus and
recombinant VV-DI4L
DEL virus post Cre passage using default
settings available in Gepard [47].
(TIFF)
Table S1 Primers used in the study.
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